Tanios Bekaii-Saab, MD

Bekaii-Saab TS et al. Practical considerations in screening for genetic alterations in cholangiocarcinoma. Ann Oncol 2021;SS0923-75434(21)00169-8. Abstract

Javle MM et al. Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement. ASCO Gastrointestinal Cancers Symposium 2021;Abstract 265.

Yoo C et al. Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin (GemCis): Multicenter comparative randomized phase 2b study (NIFTY). ASCO 2021;Abstract 4006.

Zhu AX et al. Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation. ASCO Gastrointestinal Cancers Symposium 2021;Abstract 266.

Eileen M O’Reilly, MD

Katz MH et al. Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas. ASCO Gastrointestinal Cancers Symposium 2021;Abstract 377.

Sohal DPS et al. Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: A phase 2 randomized clinical trial. JAMA Oncol 2021;7(3):421-7. Abstract

Tempero M et al. Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + gem) vs gemcitabine (gem) alone in patients with resected pancreatic cancer (PC): Updated 5-year overall survival. ESMO GI 2021;Abstract LBA-1.

van Eijck CHJ et al. Preoperative chemoradiotherapy to improve overall survival in pancreatic cancer: Long-term results of the multicenter randomized phase III PREOPANC trial. ASCO 2021;Abstract 4016.

Philip A Philip, MD, PhD, FRCP

Finn RS et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020;382(20):1894-905. Abstract

Kelley RK et al. Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design. Future Oncol 2020;16(21):1525-36. Abstract

Kelley RK et al. Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC). ASCO 2020;Abstract 4508.

Yau T et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: The CheckMate 040 randomized clinical trial. JAMA Oncol 2020;6(11):e204564. Abstract

Kim A Reiss Binder, MD

Casolino R et al. Homologous recombination deficiency in pancreatic cancer: A systematic review and prevalence meta-analysis. J Clin Oncol 2021;JCO2003238. Abstract

Golan T et al. Genomic features and classification of homologous recombination deficient pancreatic ductal adenocarcinoma. Gastroenterology 2021;160(6):2119-32. Abstract

Javle M et al. Olaparib monotherapy for previously treated pancreatic cancer with DNA damage repair genetic alterations other than germline BRCA variants: Findings from 2 phase 2 nonrandomized clinical trials. JAMA Oncology 2021;7(5):693-9. Abstract

Reiss KA et al. Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2. J Clin Oncol 2021;39(22):2497-505. Abstract